ReviewCureus2025
A Systematic Review on the Effect of Colchicine in Cardiovascular Disease Management: From Risk Reduction to Comprehensive Care.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation plays an essential role in the pathogenesis of cardiovascular diseases (CVDs), and despite advances in treatments, challenges still exist. Recent studies have explored the use of colchicine in reducing the risk of CVDs. Therefore, the present systematic review aimed to evaluate the impact of colchicine in terms of efficacy, safety, and therapeutic role in managing CVD patients. A comprehensive literature search was performed from different electronic databases, such as PubMed, Scopus, and the Cochrane Library, using keywords associated with the aim of the study, using Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA). Methodological quality assessment was performed using the Cochrane risk of bias-2.0 (RoB-2.0) and the Risk of Bias in Non-Randomized Studies-Intervention (ROBINS-I) tools for randomized controlled trials (RCTs) and non-RCTs, respectively. For the meta-analysis, RevMan 5.4 was used to construct forest plots. Finally, 19 studies were included for qualitative and quantitative analyses. Both male and female patients were included in the studies; however, studies were more skewed toward male patients reported with different types of CVDs, including acute pericarditis, coronary artery disease (CAD), heart failure, and myocardial infarction, and also reported comorbidities, like hypertension (HTN), diabetes, and dyslipidemia. Overall, a low dose of 0.5 mg/daily of colchicine was used. A high adherence rate (>85%) was observed in the studies, with few cases of discontinuation of medications. Numerous studies have reported that colchicine successfully benefits in reducing the inflammatory and other biomarkers, such as C-reactive protein (CRP), Interleukin (IL)-6, and IL-1β. The pooled estimate size for comorbidities, like diabetes, was 0.94, odds ratio (OR) (95% CI, 0.86-1.02, p = 0.13, I
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.